These Terms govern your use of the editorial reference published at Sermorelin Therapy Editorial. By reading, browsing, downloading, or otherwise interacting with the pages of this site, you agree to the conditions set out below. If you do not agree, please stop using the site.
1. Acceptance and scope. Sermorelin Therapy Editorial is an independent editorial reference covering sermorelin therapy and growth hormone releasing peptides as they are practiced in the United States. The site is provided to you as a single integrated work; you may not separate it into components without our permission. These Terms apply to every page, every embedded asset, and every interaction with the contact form.
2. Editorial purpose. The site exists to summarise published clinical literature, regulatory guidance, and reporting on the broader peptide therapy field. It is written for an adult, lay audience that wants a thoughtful overview before consulting a licensed clinician. It is not a substitute for individualized medical care.
3. Intellectual property. All text, layout, illustrations, graphic elements, source code, structured data, and database choices on the site are the property of the Sermorelin Therapy Editorial editorial team or the licensors that have authorised us to use them. You may quote short passages for personal, educational, or journalistic purposes provided you cite Sermorelin Therapy Editorial and link to the source page. You may not republish entire articles, build derivative training corpora, scrape the site for commercial datasets, or otherwise reuse the material in ways that compete with the original publication, without our prior written consent.
4. No warranty. The site is provided “as is” and “as available”. We make commercially reasonable efforts to keep the editorial content accurate and current, but medicine evolves, regulatory guidance changes, and individual clinical situations vary. We make no warranty, express or implied, about the accuracy, completeness, timeliness, fitness for a particular purpose, or non-infringement of the material published here. Nothing on the site is medical advice; see the Disclaimer page for a full statement.
5. Limitation of liability. To the maximum extent permitted by law, neither Sermorelin Therapy Editorial nor its editors, contributors, or hosting partners will be liable for any indirect, incidental, special, consequential, or punitive damages, or for any loss of profits, revenues, data, or goodwill, arising from your use of the site or your reliance on its content. Your sole and exclusive remedy for any dissatisfaction with the site is to stop using it.
6. Third-party links. The site links to external resources — clinical journals, regulatory agencies, professional societies, and news outlets — as a service to readers. We do not control those destinations and we are not responsible for their content, security, or privacy practices.
7. Conduct. When you interact with the contact form, you agree not to submit unlawful, harassing, defamatory, or fraudulent content; not to impersonate another person; and not to attempt to probe, scan, or otherwise interfere with the technical operation of the site.
8. Governing law. These Terms are governed by the laws of the United States and, where applicable, by the law of the state in which the editorial team is registered, without regard to conflict-of-laws principles. Any dispute that cannot be resolved through good-faith correspondence will be brought before the competent courts of that jurisdiction.
9. Modifications. We may update these Terms to reflect editorial, legal, or technical changes. Material changes will be summarised at the top of the page or announced through the site’s normal channels. Continued use of the site after a change constitutes acceptance of the revised Terms.
10. Contact. Questions about these Terms should be addressed to Sermorelin Therapy Editorial, Sermorelin Therapy Editorial
1209 Orange Street
Wilmington, DE 19801
United States, phone +1 (302) 555-0148, or through the form on the page.
The brief in the United States, USA
Sermorelin is a synthetic 29 amino acid peptide that copies the first portion of natural growth hormone releasing hormone. Administered as a small subcutaneous injection at night, it signals the pituitary gland to release the body's own growth hormone in a pulsatile, physiologic rhythm. That mechanism is the entire reason adults consider it.
Unlike injected human growth hormone, sermorelin keeps the body's natural feedback loop intact. The pituitary continues to regulate output. Levels rise within a window that resembles a younger adult's overnight pulse, then fall. Recovery, sleep depth, body composition and skin quality are the outcomes most commonly described.
For adults across the United States, USA, sermorelin is dispensed exclusively as a compounded preparation by licensed 503A and 503B pharmacies, after a US-licensed clinician writes a prescription. The branded sermorelin product approved decades ago was discontinued. The current treatment requires a real consultation, a real lab panel, and a real prescription. None of that is bypassed by telehealth.
Mechanism, in plain words
Natural growth hormone is released by the pituitary in short overnight pulses. With age, the size and frequency of these pulses fall. Output at 55 looks nothing like output at 25. Most of the visible age signals associated with growth hormone decline, from softer sleep to slower healing to gradual fat redistribution, follow from that drop.
Sermorelin asks the pituitary to do its old job. It binds the same receptor that natural GHRH binds, and triggers the same release. Because the body's negative feedback loop remains in place, sermorelin cannot push growth hormone past the body's own safety ceiling. This is the structural reason it is generally considered safer than injected synthetic HGH.
What it is not
Sermorelin is not anabolic in the way testosterone is anabolic. It is not a fat loss drug. It is not a performance enhancer, and is not legally prescribed for that purpose. It is not a substitute for sleep, training, or protein. It is also not a quick result. The body needs months to fully translate restored GH pulses into measurable change.
Where the evidence sits
The clinical record on sermorelin runs back to the late 1970s, when GHRH-29 was first synthesized. Trials in growth hormone deficient children supported FDA approval of the branded form. In adults, the strongest peer-reviewed evidence covers a narrower set of outcomes, primarily IGF-1 response, body composition changes over 12 to 24 weeks, and self-reported sleep and recovery quality.
Three considerations belong in any honest reading. First, modern compounded sermorelin is not a separately approved drug. Second, most public testimonials on the wellness side conflate sermorelin with the broader peptide stack patients also use. Third, the published evidence does not support sermorelin as a cosmetic anti-aging treatment, and credible providers do not market it as one.
Sermorelin is a tool for restoring physiologic pulses, not a tool for pushing growth hormone past where the body would naturally take it. The clinical case is honest only when framed that way.
The standard protocol
A first cycle generally runs 12 weeks, with a follow-up IGF-1 lab drawn at the end. Doses are dialed by the prescribing clinician based on baseline labs, body weight, and tolerance. The most common pattern in current US telehealth practice looks like this.
- Intake and baseline labHealth questionnaire on energy, sleep, recovery, training, sexual function. Baseline IGF-1, fasting glucose, complete metabolic panel, lipid panel.
- Clinician reviewA licensed clinician confirms medical appropriateness. If not appropriate, the consultation is refunded. If appropriate, dose is calculated.
- DispensingCompounded sermorelin acetate is mailed from a 503A or 503B partner pharmacy with insulin syringes, alcohol pads, sharps container.
- Self-administrationSingle subcutaneous injection at night, on an empty stomach. Standard schedule, five nights on and two nights off. Twelve weeks.
- ReassessmentFollow-up IGF-1 at week 12. Dose held, raised, lowered, or paused based on labs and self-reported response.
How to obtain a real prescription
Legitimate sermorelin in the United States moves through a narrow channel. A licensed clinician in your state writes a prescription to a registered compounding pharmacy. Anything outside that channel, especially products purchased from research peptide vendors without prescription, sits outside the medical and legal model.
The telehealth provider referenced on this site operates in all 50 states, runs the intake through a licensed clinician, uses 503A and 503B partner pharmacies, and issues a full refund if the clinical decision is that sermorelin is not appropriate. That last point matters. A provider unwilling to refuse a prescription is not practicing medicine.
Questions readers ask
Is sermorelin FDA approved?
The original branded sermorelin product was approved and is no longer sold. The form prescribed today is a compounded preparation made by licensed pharmacies under sections 503A and 503B. Compounded preparations are not separately FDA approved, and that is disclosed at consultation.
How is this different from HGH?
HGH is the growth hormone molecule itself, supplied externally. Sermorelin is a releasing peptide that prompts the body's own pituitary to make growth hormone. Sermorelin preserves the body's natural ceiling. HGH does not.
What results do adults actually report?
The most consistent reports are improved sleep depth in the first four weeks, recovery and skin quality in the second month, and body composition with modest fat loss and small lean mass gains in months three and four. Libido and joint comfort are commonly mentioned later in the cycle.
Is it safe?
Reported side effects are generally mild, the most common being mild injection site redness, transient flushing, and occasional headache. Because sermorelin works through the body's own pituitary, the negative feedback loop limits supraphysiological exposure. Clinical contraindications are screened during intake.
What does a course cost?
A standard 12 week program through US telehealth typically runs between 180 and 240 dollars per month, including the clinician visit, labs, the medication, and supplies. HSA and FSA cards are accepted at most providers. Insurance generally does not cover compounded peptides.
Is the prescription legitimate?
Yes if the provider is a licensed telehealth network using a clinician licensed in your state and a registered compounding pharmacy. A copy of the prescription accompanies the shipment. Off-channel research peptide vendors are not part of this model.
Is sermorelin legal where I live?
Sermorelin is legal across the United States when prescribed by a US-licensed clinician. The compounded preparation is dispensed under federal sections 503A and 503B, and the prescription is written by a clinician licensed in your jurisdiction.
Speak with a licensed clinician in the United States, USA
Online intake, blood panel, a real clinical decision. If sermorelin is not for you, you are not prescribed it.
Start your consultation